Theme: Recent Advances and Innovations in Pharmaceutical Science, Biopharmaceutical Drug Life Within Drugs.

Biopharma 2023

Biopharma 2023

The "3rd International Conference and Expo on Biopharmaceutics and Biologic Drugs" will take place in Singapore City, Singapore, from August 14–15, 2023, and will feature timely keynote exhibitions, oral talks, poster presentations, and presentations. We invite all participants from around the world to attend. With the assistance of 1000 additional scientific societies, organises a conference of 1000+ global events, including 600+ conferences, 500+ upcoming and past symposiums and workshops, and publishes more than 700+ open access journals, the editorial boards of which include more than 50000 well-known figures and renowned scientists.

The audience can participate in interactive panel discussions, keynote lectures, plenary talks, and poster meetings at Biopharma 2023. These topics include biopharmaceutics, drug delivery systems, novel approaches in biopharma, clinical trials on biopharmaceutical products, analytical characterization of biotherapeutics, current issues in bioequivalence of oral products, biosimilar and biologic drugs, and contemporary science. The conference brings together attendees from biopharmaceutical research facilities, pharmacists, academics, clinicians, researchers, health care professionals, students, business delegates, and young researchers from all over the world, offering a better platform for relating current research, technological advancements in the field, and therapeutic aspects.

Internationally renowned professors, scientists, researchers, students, and biopharmaceutics will gather at the Biopharma 2023 conference to discuss approaches to a range of biopharmaceutical and health-related problems. To keep biopharmaceutical specialists informed about issues affecting disease expectations, detection, and treatment, we intend to offer a variety of materials.

The speakers at this conference are well-known and knowledgeable, and they will discuss both general and niche areas of interest. Our conference's main objectives are to give professionals involved in biopharmaceutical health issues, such as specialists, nurses, technologists, and homoeopaths, the chance to discuss interventional procedures, learn about new and advanced derma practises and their effectiveness and efficiency in treating various cases, and comprehend local realities and practical limitations in treatment.

Contact us:

Bella Winget | Program Manager 
Biopharma 2023
Mail us: | WhatsApp:  +44 7915 648218

The scientific community is focused on learning about changes in the pharmaceutical industry. This is your best chance ever to connect with the biggest group of participants. We anticipate having attendees from all over the world, including well-known speakers and distinguished delegates, who will share their valuable presentations and energise the scientific community. The two-day Biopharma 2023 conference offers the chance to give presentations, disseminate information, network with potential scientists, make a splash with novel ideas, and gain notoriety and recognition. The conference's standout features include renowned speakers, the newest developments, and the most advanced techniques. The conference provides a forum for pharmacy researchers from a variety of scientific backgrounds to present their research findings, which can also be made by young researchers.

The primary goal of the conference is to disseminate information on biopharmaceuticals and biotherapeutics. An international conference on biopharmaceuticals and biologic drugs would be the ideal setting for knowledge exchange.

Directors, Business Intelligence consultants, managers of distinct business units, administrators, and overall producers or marketers of client products. Retailers, marketing agency executives, providers of solutions (digital and mobile technology, P-O-P style, retail style, and retail execution), professors, and students from around the world studying the field of marketing and advertising

The size of the global biologics contract development market was estimated at USD 5.5 billion in 2021; over the course of the forecast period, it is expected to grow at a compound annual growth rate (CAGR) of 10.5%. The market is being driven by elements like rising M&A activity, expanding adoption of cutting-edge technologies for biological production, an increase in the outsourcing of R&D by pharmaceutical and biopharma companies, and a supportive regulatory environment for clinical trials in developing nations. In the years following COVID-19, CROs are attempting to increase their global footprint in order to strengthen their position in the market. For example, in July 2022, CRO Novotech increased its presence in the US by purchasing CRO NCGS, which offered research services in the fields of haematology, infectious disease, oncology, and the central nervous system. SuchPharma and biopharma outsourcing has increased as a result of more mergers and collaborations, with major industry players moving into developing nations. To strengthen its position in the gene therapy market, Thermo Fisher Scientific, Inc., for instance, acquired Brammer Bio in May 2019. Brammer Bio is a leading viral vector contract developer for gene and cell therapies.

There is a steady increase in the prevalence of diseases like neurological disorders, gynaecological disorders, cancer, ophthalmic disorders, and cardiovascular disorders. For instance, the WHO reports that one of the leading causes of death worldwide and the cause of more than 10 million deaths in 2020 was cancer. According to Cancer Tomorrow, more cancer cases are anticipated in the years to come. Over 19.3 million cases of cancer were reported in 2020, and according to estimates from Cancer Tomorrow, this number is projected to increase to 30.2 million by 2040. In these situations, healthcare CDMOs are essential to the patient's care because many biopharma companies want to create cutting-edge treatments or ground-breaking products.

According to the Pharma R&D Annual Review 2021, the number of drugs in development is consistently rising. For instance, there were 17,737 drugs in development in 2020, but there were over 18,582 by 2021. There will likely be opportunities for market expansion as the number of drugs in development increases.

Additionally, developing nations like India and China have shown to be a desirable option for outsourcing clinical trials due to their large populations and diverse disease burdens, which facilitates the conduct of effective clinical studies and makes patient recruitment simple. According to Pharmaceutical Outsourcing, China, India, and Korea continue to be the most popular locations for clinical research outsourcing because they are the developing countries with the most active clinical trial sites due to improved market access. These nations' governments encourage outsourcing because it attracts foreign investment. Additionally, regulatory bodies in developing nations are aligning their practises with EMA and FDA requirements, speeding up the approval process and establishing credibility. thereby encouraging market expansion in these nations.

At the beginning of the pandemic, there was a significant need for COVID-19 vaccines. This has led to partnerships and collaboration agreements between several CROs, which will hasten the development of COVID-19 vaccines in 2020. However, CROs are forming alliances for the study of other diseases like cancer, Alzheimer's, and other diseases in the post-pandemic era. For instance, in April 2022, Labcorp and Xcell Biosciences partnered to help the latter's efforts to create cell and gene therapies for the treatment of Parkinson's, cancer, and other uncommon diseases. This should advance the study of these illnesses in the post-pandemic era.

Source Insights

In 2021, the microbial source market has seen a sizable share increase. Recombinant protein therapeutics are frequently created in microbial systems. Approximately 400 of the 650 protein drugs that have received global approval to date came from microbial recombinant technologies. Additionally, microbial sources, which are primarily used by CDMOs to produce cytokines, hormones, enzymes, and MABs, account for about 48.0% of biologics that have been given manufacturing approval. These elements are promoting the segment's expansion

For more information about Market Analysis click here to : Read More

The ACADEMIC / STUDENT / BUSINESS Category of Biopharma 2023 offers the participants a variety of modes or ways to participate, such as Delegate or Speaker. Online Power Point presentations and video presentations on Cisco Webinars are the mode of participation.

  • Keynote speaker: 45-50 minutes
  • Speaker (oral presentation): 25-30 minutes (only one person can present)
  • Speaker (workshop): 45-50 minutes (more than 1 can present)
  • Speaker (special session): 45-50 minutes (more than 1 can present)
  • Speaker (symposium): more than 45 minutes (more than 1 can present)
  • Delegate(only registration): will have access to all the sessions with all the benefits of registration
  • Poster presenter:  can present a poster and enjoy the benefits of delegate
  • Remote attendance:  can participate via video presentation or e-poster presentation
  • Exhibitor: can exhibit his/her company’s products by booking exhibitor booths of different sizes
  • Media partner
  • Sponsor
  • Collaborator


  • Use DOI to publish your abstract
  • Obtain certification for your involvement
  • Lower Prices Affordable Dismantle geographic barriers
  • Convenience from the comfort of your home or place of employment
  • They've Been Archive: the capability of watching events recorded
  • Excellent source for learning new professional skills
  • Study the Experts
  • Research exposure on a global scale Establish new connections
  • Considerable time savings greater engagement More Engaging Reach
  • Identify yourself as the authority
  • Get your abstracts published in international journals with a special DOI.
  • Receive discounts of up to 50% when you publish your entire essay in one of our open access international journals.
  • Obtain manuals and conference tools.
  • Obtain access to the global network of illustrious individuals.


Biopharma 2023 Report

We have presented the 2nd International Conference & Expo on Biopharmaceutics and Biologic Drugs from August 2-3, 2021 in Copenhagen, Denmark. The Organizing Committee Members, as well as scientists, researchers, students, and leaders from many sectors of biopharmaceutics, biotech, medical, and pharmacy, gave generous responses and active involvement, making this event a huge success, expresses its profound gratitude to organisations such as Pharma Voice, Event listing sites, and other notable individuals that helped promote the conference through various online and offline channels, allowing it to reach every part of the globe. The meeting consisted of several sessions in which the following important scientific tracks were discussed:

Contact us on Whatsapp: +44 7915 648218

Bella Winget

Program Manager

Biopharma 2023


For Abstract Submission:






To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date August 14-15, 2023
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1
Poster Opportunity Closed Click Here to View